FTSE Held Back as AstraZeneca Slumps on $400bn Bristol Myers Talks

Why AstraZeneca and Cheaper Oil Are Holding the FTSE Back

London's blue-chip index opened the European session in the red while its German and French counterparts rallied, with the DAX and CAC each up more than 1 per cent in early trade. The divergence is not a sign of weak UK fundamentals: construction and industrial shares were among the risers. Instead, two heavyweights are holding the FTSE 100 down — its second-largest listed company and the oil price.

AstraZeneca fell roughly 6 per cent after confirming it is considering a $400bn merger with US rival Bristol Myers Squibb. A decline of that size from a company of AstraZeneca's scale is enough to offset gains across a broad swathe of the index. The talks are at the consideration stage, with no terms agreed and no certainty a transaction will emerge.

The other drag is crude. Brent has retreated to about $83 a barrel after briefly trading above $100 during the past two weeks, when hostilities in the Middle East resumed. US President Donald Trump cancelled a large military offensive against Iran and said the country would return to the negotiating table, unwinding much of the war premium. Trade has continued passing through the Strait of Hormuz despite attacks, and talk of re-opening the waterway is still under way.

The FTSE's record high last week owed something to its lack of AI-heavy tech names during the global tech sell-off. That gap has become a drag as tech recovers on better-than-expected results from Microsoft and Amazon, with hyperscalers showing their massive capital spending programmes are converting into profits. Sentiment remains fragile: South Korea's Kospi fell more than 4 per cent on Monday, days after swinging just as violently in the other direction. The coming days shift the focus to the US, with three labour-market reports ahead of the Federal Reserve's September meeting.

What a $400bn Pharma Tie-Up, Falling Brent and a Hawkish Fed Mean for Markets

AstraZeneca: A $400bn Question at the Centre of the FTSE

The proposed tie-up is at the scale of the largest pharmaceutical deals in history, and the market's reaction shows why it matters well beyond pharma. AstraZeneca is such a large component of the FTSE 100 that a 6 per cent move in its shares dominates the index's daily direction, whatever the wider market is doing. The strategic logic of combining with Bristol Myers Squibb lies in scale across oncology and other core franchises, but the deal is not done: 'considering' a $400bn transaction leaves enormous room for disagreement over price, financing and antitrust risk. For UK index investors, the episode is also a reminder of how concentrated the benchmark has become in a handful of mega-caps whose fortunes can mask the performance of everything else.

Brent's Slide: Relief for Inflation, Pain for London's Oil Stocks

The move from above $100 to $83 in the space of two weeks is the mirror image of the spike that followed the resumption of hostilities. Trump's decision to call off a major offensive and steer Iran back toward negotiations has removed the premium those headlines had built into crude. London's oil producers feel that directly, compounding the AstraZeneca drag on the index. But the inflationary relief is real: cheaper crude eases cost pressures at a moment when much of the recent US inflation has been driven by corporate spending, AI investment and a higher oil price rather than by consumer or wage-led demand.

Kospi: The Market's Most Honest AI Barometer

Deutsche Bank's observation that South Korean shares ended last week lower despite an 18 per cent jump on Friday captures how unstable the AI and memory-chip trade has become. After steep falls on Tuesday and Wednesday, the Kospi is now the fastest available proxy for global positioning in AI hardware and memory semiconductors. The index remains the place where shifting views on AI capital expenditure show up first — and the profit conversion visible in the Microsoft and Amazon numbers is the main reason the recovery narrative is holding so far. This week's relative calm reflects the pivot back to US macro data, but the volatility is unlikely to be over.

The Fed's Uncomfortable September Setup

The Federal Reserve held rates last week, but the vote contained a notable push for tightening, with three FOMC members opting to raise. Chair Kevin Warsh has given no firm signal either way, and the next meeting is not until September. This week's trio of reports — JOLTS on Tuesday, ADP on Wednesday and non-farm payrolls on Friday — will therefore carry outsized weight. The complication is that US inflation is currently being driven by corporate spending, AI investment and a higher oil price rather than by consumer or wage pressure. If employment data weaken, the Fed would face the awkward combination of sticky corporate-driven prices and a softening labour market: a rate rise could feel wrong, but the inflation signal would argue for one. Expect volatility around every print.

What Investors Should Watch: US Jobs, Oil Levels and the AstraZeneca Deal

The week's market-moving events are concentrated in the US calendar, with Asia and the AstraZeneca deal talks as the main wildcards for London-listed portfolios.

• Tuesday's JOLTS report, Wednesday's ADP figures and Friday's non-farm payrolls will shape expectations for the Fed's September meeting, where three members already voted to raise rates; hot readings raise the odds of a move.
• Chair Kevin Warsh remains uncommitted, so any public comment near the data releases is likely to move rate-sensitive assets more than the prints themselves.
• Brent at $83 after a brief spell above $100 means further progress in Strait of Hormuz re-opening talks would keep London's oil stocks under pressure, while offering a tailwind for inflation-sensitive trades.
• AstraZeneca's 6 per cent drop illustrates the FTSE's concentration risk; the index's near-term direction depends heavily on whether the $400bn Bristol Myers Squibb talks progress or collapse.
• For AI and memory-chip exposure, treat the Kospi as the most current sentiment gauge: after Friday's 18 per cent rebound and Monday's 4 per cent-plus fall, expect continued two-way swings.